ArticleAmerican journal of respiratory and critical care medicine2022
Thromboxane-Prostanoid Receptor Signaling Drives Persistent Fibroblast Activation in Pulmonary Fibrosis.
Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in American journal of respiratory and critical care medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05571059 (A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Determine the Safety and Efficacy of Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis), which is not on this map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Determine the Safety and Efficacy of Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Structural and dynamic insights into agonist recognition and function of the thromboxane ANature communications · 2026Article
- Most Promising Emerging Therapies for Pulmonary Fibrosis: Targeting Novel Pathways.Biomedicines · 2026Review
- Acute exacerbation of idiopathic pulmonary fibrosis: application of the diagnostic criteria and the role of respiratory intermediate care unit and mechanical ventilation.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Emerging therapies for the treatment of systemic sclerosis.Nature reviews. Rheumatology · 2025Review
- Emerging Concepts in Therapeutic Interventions for Idiopathic Pulmonary Fibrosis.Seminars in respiratory and critical care medicine · 2025Review
- Idiopathic Pulmonary Fibrosis, Today and Tomorrow: Certainties and New Therapeutic Horizons.Pulmonary therapy · 2025Review
- Formononetin-Loaded PLGA Large Porous Microparticles via Intratracheal Instillation for Bleomycin-Induced Pulmonary Fibrosis Treatment.AAPS PharmSciTech · 2025Article
- Vascular involvement in idiopathic pulmonary fibrosis.ERJ open research · 2024Review
- Pathogenesis and Therapy of Hermansky-Pudlak Syndrome (HPS)-Associated Pulmonary Fibrosis.International journal of molecular sciences · 2024Review
- Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF).Expert review of clinical pharmacology · 2024Review
- Blockade of thromboxane A2 signaling attenuates ethanol-induced myocardial inflammatory response in mice.Alcohol, clinical & experimental research · 2024Article
- Animal models of acute exacerbation of pulmonary fibrosis.Respiratory research · 2023Review
- αCGRP deficiency aggravates pulmonary fibrosis by activating the PPARγ signaling pathway.Genes and immunity · 2023Article
- Oxidative Stress and Air Pollution: Its Impact on Chronic Respiratory Diseases.International journal of molecular sciences · 2023Review
- The Role and Regulation of Thromboxane AMolecules (Basel, Switzerland) · 2022Review
- From Biomarker to Mechanism? F2-isoprostanes in Pulmonary Fibrosis.American journal of respiratory and critical care medicine · 2022Article
- Physiological Effects of Ferroptosis on Organ Fibrosis.Oxidative medicine and cellular longevity · 2022Review
Corrections and comments
- Commented on by
Authors and funding
22 authors at 7 institutions in 3 countries.
Toshio SuzukiDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, and.
Jonathan A KropskiDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, and.
Jingyuan ChenDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, and.
Erica J CarrierDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, and.
Xinping ChenDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, and.
Taylor P SherrillDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, and.
Nichelle I WintersDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, and.
Jane E CamarataDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, and.
Vasiliy V PolosukhinDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, and.
Wei HanDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, and.
Anandharajan RathinasabapathyDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, and.ORCID 0000-0002-3474-8063
Sergey GutorDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, and.ORCID 0000-0003-4402-0516
Peter GullemanDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, and.
Carleen SabusapDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, and.
Nicholas E BanovichTranslational Genomics Research Institute, Phoenix, Arizona.
Harikrishna TanjoreDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, and.
Michael L FreemanDepartment of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
Yuji TadaDepartment of Pulmonary Medicine, School of Medicine, International University of Health and Welfare, Chiba, Japan; and.
Lisa R YoungDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, and.
Jason J GokeyDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, and.
Timothy S BlackwellDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, and.
James D WestDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, and.
Pulmonary and Allergy Associates · USVanderbilt University · USChildren's Hospital of Philadelphia · USInternational University of Health and Welfare · JPTranslational Genomics Research Institute · USUniversity of Tsukuba · JPVanderbilt University Medical Center · US
Funding
Sex Hormones in Pulmonary Arterial HypertensionP01HL108800 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HEMNES, ANNA R · 2012 to 2021
$22.0MMechanisms of Familial Pulmonary FibrosisP01HL092870 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BLACKWELL, TIMOTHY S. · 2010 to 2020
$21.6MInterventions Against the Molecular Etiology of BMPR2-induced PAHR01HL095797 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WEST, JAMES D · 2010 to 2022
$6.7MInterdisciplinary Training Program in Lung ResearchT32HL094296 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ray Stokes Peebles · 2008 to 2026
$6.3MSpatiotemporal genomic regulation of disease initiation and progression in pulmonary fibrosisR01HL145372 · NHLBI · TRANSLATIONAL GENOMICS RESEARCH INST · PI Nicholas Eli Banovich, Jonathan Andrew Kropski · 2019 to 2026
$6.0MMechanisms of Pulmonary Fibrosis in Hermansky-Pudlak SyndromeR01HL119503 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI YOUNG, LISA R. · 2013 to 2021
$3.6MMechanisms of epithelial repair and remodeling in pulmonary fibrosisR01HL153246 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KROPSKI, JONATHAN ANDREW · 2020 to 2024
$2.8MRole of the thromboxane prostanoid receptor in right ventricular adaptation to pressure overloadR01HL135011 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CARRIER, ERICA J · 2017 to 2021
$2.2MThromboxane Receptor Signaling in Pulmonary FibrosisR01HL151016 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KROPSKI, JONATHAN ANDREW · 2020 to 2023
$2.1MDNA-Damage Repair In Pulmonary FibrosisK08HL130595 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KROPSKI, JONATHAN ANDREW · 2016 to 2020
$786kMidcareer Investigator Award in Patient-Oriented Research in Pediatric Rare Lung DiseasesK24HL143281 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI YOUNG, LISA R. · 2018 to 2022
$540kNHLBI NIH HHS K08 HL130595NHLBI NIH HHS K08HL130595NHLBI NIH HHS K24 HL143281NHLBI NIH HHS K24HL143281NHLBI NIH HHS P01 HL092870NHLBI NIH HHS P01HL092870NHLBI NIH HHS P01 HL108800NHLBI NIH HHS P01HL108800NHLBI NIH HHS R01 HL095797NHLBI NIH HHS R01 HL119503NHLBI NIH HHS R01HL119503NHLBI NIH HHS R01 HL135011NHLBI NIH HHS R01HL135011NHLBI NIH HHS R01 HL145372NHLBI NIH HHS R01HL145372NHLBI NIH HHS R01 HL151016NHLBI NIH HHS R01HL151016NHLBI NIH HHS R01 HL153246NHLBI NIH HHS T32 HL094296NHLBI NIH HHS T32HL094296
Abstract
PubMed holds no abstract for this paper.
Indexed as
Idiopathic Pulmonary FibrosisReceptors, ThromboxaneAnimalsBleomycinF2-IsoprostanesFibroblastsHumansLungMiceMice, Inbred C57BLProstaglandinsThromboxanesTransforming Growth Factor betaBleomycinF2-IsoprostanesProstaglandinsReceptors, ThromboxaneThromboxanesTransforming Growth Factor betaHermansky-Pudlak syndromeIPFoxidative stressthromboxane–prostanoid receptortransforming growth factor-β
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT05571059ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.